AVX-001

DB19194InvestigationalSmall molecule

AVX-001 is under investigation in clinical trial NCT05164393 (Phase I/iia Trial to Evaluate AVX001 Gel in Doses of 1% or 3% Compared With Vehicle Over Four Weeks of Field-directed Treatment...

Mechanism: Pharmacologically active on Cytosolic phospholipase A2
Curator reviewed
Formula / weight: C₂₁H₂₉F₃OS · 386.52 g/mol (avg)
Also known as: 1-((2e,6z,9z,12z,15z)-octadeca-3,6,9,12,15-pentaen-1-thio)-3,3,3-trifluoroacetone · 2-propanone, 1,1,1-trifluoro-3-((2e,6z,9z,12z,15z)-2,6,9,12,15-octadecapentaenylthio)-
Code names: AKH-217 · AVX-001

Resolves to

Compound

UNIIG8333V26KKCAS300553-18-8ChEMBLCHEMBL5095215

Structure

InChIKeyRBPYIYOPSGHFQG-IIFHDYRKSA-NSMILESCC\C=C/C\C=C/C\C=C/C\C=C/CC\C=C\CSCC(=O)C(F)(F)F

Targets

P47712PLA2G4A

What you can answer from here — as of July 21, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

1Clinical trialPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with AVX-001, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account